1362 related articles for article (PubMed ID: 3091760)
21. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
[TBL] [Abstract][Full Text] [Related]
22. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the rat: characterization and age-dependent effects.
Jarvis MF; Wagner GC
Synapse; 1990; 5(2):104-12. PubMed ID: 2309157
[TBL] [Abstract][Full Text] [Related]
23. A simple quantitative bradykinesia test in MPTP-treated mice.
Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
[TBL] [Abstract][Full Text] [Related]
24. 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl)pyridine: studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Finnegan KT; Irwin I; Delanney LE; Ricaurte GA; Langston JW
J Pharmacol Exp Ther; 1987 Sep; 242(3):1144-51. PubMed ID: 3498815
[TBL] [Abstract][Full Text] [Related]
25. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
26. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
[TBL] [Abstract][Full Text] [Related]
27. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
28. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
[TBL] [Abstract][Full Text] [Related]
29. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Smith L; De Salvia M; Jenner P; Marsden CD
Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
[TBL] [Abstract][Full Text] [Related]
30. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
[TBL] [Abstract][Full Text] [Related]
31. MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
Viaggi C; Vaglini F; Pardini C; Caramelli A; Corsini GU
Neuropharmacology; 2009 Jun; 56(8):1075-81. PubMed ID: 19298832
[TBL] [Abstract][Full Text] [Related]
32. [Experimental models, of Parkinson disease].
Luquin MR
Rev Neurol; 2000 Jul 1-15; 31(1):60-6. PubMed ID: 10948587
[TBL] [Abstract][Full Text] [Related]
33. [Experimental model of Parkinson disease: mechanisms and anatomo- pathological characteristics of MPTP neurotoxicity].
Herrero MT; Luquín MR; Obeso JA
Arch Neurobiol (Madr); 1992; 55(4):175-82. PubMed ID: 1417423
[TBL] [Abstract][Full Text] [Related]
34. Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites.
Przedborski S; Jackson-Lewis V; Popilskis S; Kostic V; Levivier M; Fahn S; Cadet JL
Neurochirurgie; 1991; 37(6):377-82. PubMed ID: 1780015
[TBL] [Abstract][Full Text] [Related]
35. A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) within catecholaminergic neurons.
Johannessen JN
Neurotoxicology; 1991; 12(2):285-302. PubMed ID: 1956587
[TBL] [Abstract][Full Text] [Related]
36. MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects.
Langston JW; Langston EB; Irwin I
Acta Neurol Scand Suppl; 1984; 100():49-54. PubMed ID: 6333134
[TBL] [Abstract][Full Text] [Related]
37. Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP.
Da Prada M; Kettler R; Keller HH; Bonetti EP; Imhof R
Adv Neurol; 1987; 45():175-8. PubMed ID: 2881442
[No Abstract] [Full Text] [Related]
38. [Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease].
Brücke T; Riederer P
Wien Med Wochenschr; 1986 Aug; 136(15-16):401-8. PubMed ID: 2878540
[TBL] [Abstract][Full Text] [Related]
39. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
Forno LS; Langston JW; DeLanney LE; Irwin I; Ricaurte GA
Ann Neurol; 1986 Oct; 20(4):449-55. PubMed ID: 3024555
[TBL] [Abstract][Full Text] [Related]
40. [The life history of brain dopamine].
Hornykiewicz O
Wien Klin Wochenschr; 1985 Apr; 97(8):350-4. PubMed ID: 2986364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
